Free Trial

Gene Biotherapeutics (CRXM) News Today

Gene Biotherapeutics logo
Gene editing pioneer back as CEO of ChristianaCare spinoff
Taysha Gene Therapies price target raised to $8 from $6 at Canaccord
Get Gene Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRXM and its competitors with MarketBeat's FREE daily newsletter.

Missed Nvidia? Buy Elon Musk’s “Silent Partner” (Ad)

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

CRXM Media Mentions By Week

CRXM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRXM
News Sentiment

0.00

0.60

Average
Medical
News Sentiment

CRXM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRXM Articles
This Week

2

11

CRXM Articles
Average Week

Get Gene Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRXM and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (OTCMKTS:CRXM) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners